Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

2.970 +0.300 (+11.24%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,418,408
Open 2.730
Bid (Size) 2.950 (2)
Ask (Size) 2.990 (45)
Prev. Close 2.670
Today's Range 2.670 - 3.045
52wk Range 1.250 - 6.790
Shares Outstanding 283,162,902
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Recap: Agenus Q2 Earnings
  Agenus (NASDAQ:AGEN) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga

Performance

YTD
-14.41%
-14.41%
1 Month
+2.77%
+2.77%
3 Month
+82.21%
+82.21%
6 Month
+21.72%
+21.72%
1 Year
-50.08%
-50.08%

More News

Read More
Agenus Commences Initial-Stage Advanced Tumors Study
Via Benzinga
Agenus to Provide Corporate Update and Second Quarter 2022 Financial Report
From Agenus Inc.
Via Globe NewsWire
U.S. Stocks Turn Negative; 2U Shares Spike Higher
Via Benzinga
Recap: Agenus Q1 Earnings
Via Benzinga
Recap: Agenus Q4 Earnings
Via Benzinga
Alphabet, Dyne Therapeutics And 74 Biggest Movers From Yesterday
Via Benzinga
Why Is Allena Pharmaceuticals Jumping By 207%? 45 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
Via Benzinga
Agenus Touts 'Unprecedented Activity' For Botensilimab/Balstilimab Combo In Colorectal Cancer
Via Benzinga
Earnings Scheduled For March 1, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Agenus's Return On Capital Employed Insights
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
Looking Into Agenus's Return On Capital Employed
Via Benzinga
41 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
Agenus inc (AGEN) Q3 2021 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021
Via Benzinga
Agenus Posts Early Data For CTLA-4 Drug Candidate Across Tumor Types
Via Benzinga
Why Agenus Was Rising High on Tuesday
Via The Motley Fool
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Via Benzinga
55 Biggest Movers From Friday
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.